<DOC>
	<DOCNO>NCT01001104</DOCNO>
	<brief_summary>The main purpose study ass dose-response characteristic Japanese patient Type 2 Diabetes take LY2189265 monotherapy .</brief_summary>
	<brief_title>A Study LY2189265 Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>Japanese patient type 2 diabetes body mass index ( BMI ) ≥18.5 kilogram per square meter ( kg/m^2 ) &lt; 40.0 kg/m^2 . Patients oral antidiabetic drug ( OAD ) naïve take OAD monotherapy except dipeptidyl peptidase4 inhibitor ( DPPIV ) willing discontinue OAD . Patients OAD naïve screen glycosylated hemoglobin ( HbA1c ) value 7.0 % 9.5 % randomization HbA1c value 7.0 % 9.5 % , take OAD monotherapy screen HbA1c value 6.0 % 8.5 % randomization HbA1c value 7.0 % 9.5 % . Patients , opinion investigator , stable weight 12 week prior screen . Patients currently take prescription medication promote weight loss Patients receive chronic systemic glucocorticoid therapy , receive therapy within 4 week immediately prior screening . Patients know clinically significant gastrointestinal disorder , undergone excision part gastrointestinal tract , undergone gastric bypass surgery treatment obesity , chronically take drug directly influence gastrointestinal motility . Patients poorly control hypertension , renal artery stenosis , evidence labile blood pressure include symptomatic postural hypotension . Patients obvious clinical sign symptom pancreatitis , history chronic pancreatitis acute pancreatitis . Patients amylase and/or lipase 1.5 time upper limit reference range . Have family history , obvious clinical sign , symptom medullary carcinoma thyroid .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Diabetes</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Lilly</keyword>
</DOC>